The joint venture company will be co-located at BBA’s Massachusetts & California facilities and staffed by experienced regulatory and quality professionals who will have a dedicated focus on Creganna-Tactx Medical customers.

Under the partnership agreement and by leveraging BBA’s extensive experience, expertise and consulting services, Creganna-Tactx Medical will provide a broad range of quality and regulatory support to its customers.

The support services include development of appropriate regulatory and clinical strategies, regulatory submission development and liaison services, management of clinical trials and associated consulting services to achieve successful product approval and commercialization support.

The service will be provided for a global market to include worldwide approval pathways and international regulatory support.

Creganna-Tactx Medical CEO Helen Ryan said the new services to be provided under the joint venture partnership perfectly complement their current service portfolio and respond to the evolving requirements of their customers.

The services to be provided under the joint venture partnership will be available immediately to Creganna-Tactx Medical customers.